Omeros reports robust narsoplimab EAP survival data in TA-TMA; BLA resubmission planned Q1 2025

OMEROS CORP

Combined EAP + pivotal trial vs external control: HR 0.34-0.46, p-values <0.00001 to 0.00002.
Previously untreated high-risk adults: 1-year survival 58%; children: 79% in EAP.
Refractory patients (failed complement inhibitors): 1-year survival 44% vs historical <20%.
No safety signals; BLA resubmission expected later Q1 2025, MAA submission by mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.